Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder
Autore:
Montgomery, SA; Kasper, S; Stein, DJ; Hedegaard, KB; Lemming, OM;
Indirizzi:
H Lundbeck AS, Copenhagen, Denmark H Lundbeck AS Copenhagen DenmarkH Lundbeck AS, Copenhagen, Denmark Univ Stellenbosch, Dept Psychiat, MRC, Res Unit Anxiety Disorders, Cape Town, South Africa Univ Stellenbosch Cape Town South Africa rders, Cape Town, South Africa Univ Vienna, Dept Gen Psychiat, Vienna, Austria Univ Vienna Vienna Austria v Vienna, Dept Gen Psychiat, Vienna, Austria Univ London Imperial Coll Sci Technol & Med, London, England Univ London Imperial Coll Sci Technol & Med London England don, England
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 16, anno: 2001,
pagine: 75 - 86
SICI:
0268-1315(200103)16:2<75:C2M4MA>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; DOSE FLUOXETINE; CLOMIPRAMINE; DEPRESSION; TRIAL; MULTICENTER; FLUVOXAMINE; SERTRALINE; EPIDEMIOLOGY; OUTPATIENTS;
Keywords:
citalopram; depression; obsessive-compulsive disorder; selective serotonin reuptake inhibitors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
47
Recensione:
Indirizzi per estratti:
Indirizzo: Montgomery, SA POB 8751, London W13 8WH, England POB 8751 London EnglandW13 8WH , London W13 8WH, England
Citazione:
S.A. Montgomery et al., "Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder", INT CLIN PS, 16(2), 2001, pp. 75-86

Abstract

Serotonin reuptake inhibitors appear to be uniquely effective treatments for obsessive-compulsive disorder (OCD). This double-blind, placebo-controlled study was the first trial to assess the efficacy of the most selective of the serotonin reuptake inhibitors, citalopram, in OCD. A total of 401 patients were randomized to receive citalopram 20, 40 or 60 mg/day or placebo for 12 weeks. All three doses of citalopram were significantly more effective than placebo measured on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) change score (P < 0.01). The highest response rate, defined as 25% improvement in Y-BOCS entry score, was observed in the 60 mg group (65%). This compared with 52% and 57.4% in the 40 mg and 20 mg groups. Response rate onplacebo was 36.6% (P < 0.05 for all three doses of citalopram compared to placebo). There was no significant difference between the individual doses of citalopram. An advantage was seen for citalopram on the Sheehan Disability Scale compared with placebo (P < 0.05 on all three citalopram groups versus placebo for both the work situation and the family life and home responsibilities and P < 0.05 on citalopram 60 mg and 20 mg versus placebo for the social life and home activities). Citalopram was well tolerated; only 4 to 6 patients in each dose group discontinued the study prematurely due to adverse events. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 07:32:32